HIV Treatment Scale-up in Africa: The Impact of Drug Resistance

Chapter

Abstract

The availability of antiretroviral therapy (ART) to individuals infected with HIV in many African countries has greatly increased since 2004, as result of coordinated efforts of funding agencies and individual governments in rolling out HIV care and treatment. As the numbers of individuals receiving ART rises, the long-term clinical outcomes of ART among patients on treatment, needs to be further understood. In many resource-limited countries, the data on patterns of HIV resistance to antiretroviral drugs and the effect of HIV subtype diversity on resistance remains limited. Patients’ social economic situations and deficiencies in health systems could promote non-adherence that facilitates the development of drug resistance. Here we explore available data on HIV-1 resistance to ART in Africa, in relation to the drug regimens used, HIV-1 subtype diversity and its implication on drug resistance. We specifically examine reported HIV resistance associated with treatment, transmitted resistance, and prevention of mother-to-child transmission programs. Finally, we identify specific measures both in terms of research and public health efforts to contain and prevent drug resistance development in patients on treatment.

Keywords

Toxicity Europe Transportation Tuberculosis Thymidine 

References

  1. 1.
    UNAIDS (2010) Botswana: progress towards universal access and the declaration of commitment on HIV/AIDS. UNAIDS, GenevaGoogle Scholar
  2. 2.
  3. 3.
    UNAIDS/WHO (2008) Epidemiological fact sheets on HIV and AIDS, 2008 updates. UNAIDS, GenevaGoogle Scholar
  4. 4.
    Kanki P (2009) The challenge and response in Nigeria. In: Kanki P, Marlink R (eds) A line drawn in the sand: responses to the AIDS treatment crisis in Africa. Harvard Center for Population and Development Studies, Cambridge, MA, pp 63–91Google Scholar
  5. 5.
    USAID (2008) Africa region: HIV/AIDS health profile. USAIDGoogle Scholar
  6. 6.
    TACAID (2008) Tanzania: Country progress report. UNAIDS, GenevaGoogle Scholar
  7. 7.
    Gilks CF, Crowley S, Ekpini R, Gove S, Perriens J, Souteyrand Y et al (2006) The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 368:505–510PubMedCrossRefGoogle Scholar
  8. 8.
    WHO (2006) Antiviral therapy for HIV infection in adults and adolescents: recommendations for public health approach. World Health Organization, GenevaGoogle Scholar
  9. 9.
    WHO (2010) Antiretroviral therapy for HIV infection in adults and adolescents, recommendations for a public health approachGoogle Scholar
  10. 10.
    Preston BD (1997) Reverse transcriptase fidelity and HIV-1 variation. Science 275:228–229, author reply 230–221PubMedCrossRefGoogle Scholar
  11. 11.
    Roberts JD, Bebenek K, Kunkel TA (1988) The accuracy of reverse transcriptase from HIV-1. Science 242:1171–1173PubMedCrossRefGoogle Scholar
  12. 12.
    Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123–126PubMedCrossRefGoogle Scholar
  13. 13.
    Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P et al (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117–122PubMedCrossRefGoogle Scholar
  14. 14.
    Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D et al (2007) Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med 15:119–125PubMedGoogle Scholar
  15. 15.
    Bisson GP, Frank I, Gross R, Lo Re V 3rd, Strom JB, Wang X et al (2006) Out-of-pocket costs of HAART limit HIV treatment responses in Botswana’s private sector. AIDS 20:1333–1336PubMedCrossRefGoogle Scholar
  16. 16.
    Cohen GM (2007) Access to diagnostics in support of HIV/AIDS and tuberculosis treatment in developing countries. AIDS 21(suppl 4):S81–S87PubMedCrossRefGoogle Scholar
  17. 17.
    Nugent R, Pickett J, Back E (2008) Drug resistance as global health policy priority. Center for Global Development, Washington, DCGoogle Scholar
  18. 18.
    WHO (2006) The World Health report, 2006. World Health Organization, GenevaGoogle Scholar
  19. 19.
    Breen RA, Swaden L, Ballinger J, Lipman MC (2006) Tuberculosis and HIV co-infection: a practical therapeutic approach. Drugs 66:2299–2308PubMedCrossRefGoogle Scholar
  20. 20.
    Fonjungo PN, Dash BC, Mpoudi EN, Torimiro JN, Alemnji GA, Eno LT et al (2000) Molecular screening for HIV-1 group N and simian immunodeficiency virus cpz-like virus infections in Cameroon. AIDS 14:750–752PubMedCrossRefGoogle Scholar
  21. 21.
    Jaffe HW, Schochetman G (1998) Group O human immunodeficiency virus-1 infections. Infect Dis Clin North Am 12:39–46PubMedCrossRefGoogle Scholar
  22. 22.
    Grobler J, Gray CM, Rademeyer C, Seoighe C, Ramjee G, Karim SA et al (2004) Incidence of HIV-1 dual infection and its association with increased viral load set point in a cohort of HIV-1 subtype C-infected female sex workers. J Infect Dis 190:1355–1359PubMedCrossRefGoogle Scholar
  23. 23.
    Hu DJ, Subbarao S, Vanichseni S, Mock PA, Ramos A, Nguyen L et al (2005) Frequency of HIV-1 dual subtype infections, including intersubtype superinfections, among injection drug users in Bangkok, Thailand. AIDS 19:303–308PubMedGoogle Scholar
  24. 24.
    Hemelaar J, Gouws E, Ghys PD, Osmanov S (2006) Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 20:W13–W23PubMedCrossRefGoogle Scholar
  25. 25.
    Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P et al (2006) Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367:817–824PubMedCrossRefGoogle Scholar
  26. 26.
    Essex M (2009) HIV variability in Africa. In: Kanki P, Marlink R (eds) A line drawn in the sand: responses to the AIDS treatment crisis in Africa. Harvard Center for Population and Development Studies, Cambridge, MA, pp 245–258Google Scholar
  27. 27.
    Ivers LC, Kendrick D, Doucette K (2005) Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis 41:217–224PubMedCrossRefGoogle Scholar
  28. 28.
    Kantor R, Katzenstein D (2003) Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Rev 5:25–35PubMedGoogle Scholar
  29. 29.
    Vergne L, Peeters M, Mpoudi-Ngole E, Bourgeois A, Liegeois F, Toure-Kane C et al (2000) Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol 38:3919–3925PubMedGoogle Scholar
  30. 30.
    Chaplin B, Eisen G, Idoko J, Onwujekwe D, Idigbe E, Adewole I et al (2010) Impact of HIV type 1 subtype on drug resistance mutations in nigerian patients failing first-line therapy. AIDS Res Hum Retrovir 15:1413–1420Google Scholar
  31. 31.
    Holguin A, Sune C, Hamy F, Soriano V, Klimkait T (2006) Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure. J Clin Virol 36:264–271PubMedCrossRefGoogle Scholar
  32. 32.
    Van De Vijver DA, Wensing AM, Angarano G, Asjo B, Balotta C, Boeri E et al (2006) The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr 41:352–360PubMedCrossRefGoogle Scholar
  33. 33.
    Taiwo B, Chaplin B, Penugonda S, Meloni S, Akanmu S, Gashau W et al (2010) Suboptimal etravirine activity is common during failure of nevirapine-based combination antiretroviral therapy in a cohort infected with non-B subtype HIV-1. Curr HIV Res 8:194–198PubMedCrossRefGoogle Scholar
  34. 34.
    Doualla-Bell F, Avalos A, Brenner B, Gaolathe T, Mine M, Gaseitsiwe S et al (2006) High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob Agents Chemother 50:4182–4185PubMedCrossRefGoogle Scholar
  35. 35.
    Brenner B, Turner D, Oliveira M, Moisi D, Detorio M, Carobene M et al (2003) A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 17:F1–F5PubMedCrossRefGoogle Scholar
  36. 36.
    Eshleman SH, Guay LA, Wang J, Mwatha A, Brown ER, Musoke P et al (2005) Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine: HIVNET 012. J Acquir Immune Defic Syndr 40:24–29PubMedCrossRefGoogle Scholar
  37. 37.
    Arrive E, Newell ML, Ekouevi DK, Chaix ML, Thiebaut R, Masquelier B et al (2007) Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol 36:1009–1021PubMedCrossRefGoogle Scholar
  38. 38.
    Phillips AN, Dunn D, Sabin C, Pozniak A, Matthias R, Geretti AM et al (2005) Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 19:487–494PubMedCrossRefGoogle Scholar
  39. 39.
    Seyler C, Adje-Toure C, Messou E, Dakoury-Dogbo N, Rouet F, Gabillard D et al (2007) Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa. AIDS 21:1157–1164PubMedCrossRefGoogle Scholar
  40. 40.
    Bussmann H, Novitsky V, Wester W, Peter T, Masupu K, Gabaitiri L et al (2005) HIV-1 subtype C drug-resistance background among ARV-naive adults in Botswana. Antivir Chem Chemother 16:103–115PubMedGoogle Scholar
  41. 41.
    Gordon M, De Oliveira T, Bishop K, Coovadia HM, Madurai L, Engelbrecht S et al (2003) Molecular characteristics of human immunodeficiency virus type 1 subtype C viruses from KwaZulu-Natal, South Africa: implications for vaccine and antiretroviral control strategies. J Virol 77:2587–2599PubMedCrossRefGoogle Scholar
  42. 42.
    Koizumi Y, Ndembi N, Miyashita M, Lwembe R, Kageyama S, Mbanya D et al (2006) Emergence of antiretroviral therapy resistance-associated primary mutations among drug-naive HIV-1-infected individuals in rural western Cameroon. J Acquir Immune Defic Syndr 43:15–22PubMedCrossRefGoogle Scholar
  43. 43.
    Konings FA, Zhong P, Agwara M, Agyingi L, Zekeng L, Achkar JM et al (2004) Protease mutations in HIV-1 non-B strains infecting drug-naive villagers in Cameroon. AIDS Res Hum Retrovir 20:105–109PubMedCrossRefGoogle Scholar
  44. 44.
    Vidal N, Mulanga C, Bazepeo SE, Mwamba JK, Tshimpaka J, Kashi M et al (2006) HIV type 1 pol gene diversity and antiretroviral drug resistance mutations in the Democratic Republic of Congo (DRC). AIDS Res Hum Retrovir 22:202–206PubMedCrossRefGoogle Scholar
  45. 45.
    Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC et al (2002) Antiretroviral-drug resistance among patients recently infected with HIV. New Engl J Med 347:385–394PubMedCrossRefGoogle Scholar
  46. 46.
    Wensing AM, Van De Vijver DA, Angarano G, Asjo B, Balotta C, Boeri E et al (2005) Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 192:958–966PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of Immunology and Infectious DiseasesHarvard School of Public HealthBostonUSA

Personalised recommendations